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In The Netherlands, many patients are being switched from atorvastatin to generic 
simvastatin at inferior doses, which might lead to a signiﬁcant increase in future 
cardiovascular events.
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OBJECTIVES: The objective of this study is the analysis of cardiovascular drugs 
consumption (C group) in two mid European countries, Croatia and Slovenia, for the 
9-year period (from 2000 to 2008). Further, the aim was to identify the generic drugs 
usage in each country, the price for DDD for original and generic drugs, and to identify 
the most prescribed drugs in C group. METHODS: The data on the consumption 
have been obtained from the International Medical Statistics database for Croatia and 
Slovenia. Drugs usage is presented in deﬁned daily doses per 1000 inhabitants per day 
(DDD/1000) according to the World Health Organization Collaborating Centre for 
Drugs Statistics Methodology. Financial expenditure data are presented in Euros. An 
average cost per DDD was calculated for each drug group. RESULTS: The total usage 
of cardiovascular drugs is higher in Slovenia, but the prescribed generic drugs usage 
is higher in Croatia during the investigated period i.e. in Croatia 65.07% of all pre-
scribed drugs from C group were generics in 2008., while in Slovenia it was 55.05%. 
The average price per 1 DDD, for both original and generic drugs in C group, was 
lower in Croatia. The cardiovascular drugs usage, according to C subgroups shows a 
higher prescription rate in Croatia for C01 (Cardiac therapy), C02 (Antihypertensives) 
and C09 (Agents acting on the renin-angiotensin system), while in Slovenia there is a 
higher consumption in C08 (Calcium channel blockers) and C10 (Lipid modifying 
agents). CONCLUSIONS: Comparing the cardiovascular drugs prices in both coun-
tries, there is a possibility for price reduction in Slovenia. Drugs prescription patterns 
are different in Croatia and Slovenia. This indicates the need for a more thorough 
analysis and the introduction of national drugs guidelines for rational prescribing, 
monitoring and evaluation. Although the generic drugs usage in C group is relatively 
high, it should be further supported and promoted.
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OBJECTIVES: Regular physical activity is a critical guideline-recommended compo-
nent of disease management in all patients with hypertension. We examined the 
associations of health care expenditure and resource use with physical inactivity in 
this population. METHODS: We used a nationally-representative sample from the 
2006 Agency for Health care Research and Quality Medical Expenditure Panel 
Survey(MEPS) for this retrospective study of adults (18 years or older) with a diagnosis 
of primary hypertension (ICD-9:401.x). Generalized linear modeling was used to 
assess all-cause total and out-of-pocket health care expenses and the odds of emer-
gency room visits and hospitalizations using gamma and binomial families, respec-
tively, as a function of physical inactivity (self-report of not spending ≥30 minutes in 
moderate physical activity ≥3 times per week). National population estimates were 
adjusted for demographics (age, gender, race, education, marital-status, income, 
region), payer (% coverage by public and/or private insurance), comorbidity severity 
(Deyo-Charlson index), complicating conditions (depression, diabetes, myocardial 
infarction, cerebrovascular accidents, heart failure, peripheral vascular disease), and 
antihypertensive treatment (classes). RESULTS: (reported as weighted estimates ± 
standard errors) Mean age (n = 46,884,259) was 60.8 ± 0.3 years; 23.4 ± 0.7% of 
patients had diabetes, and 13.9 ± 0.5% had depression. Some 52.8 ± 0.9% of patients 
reported being physically inactive. On average, patients had $8468 ± 257 in total, and 
$1453 ± 47 in out-of-pocket health care expenses in 2006 with 19.4 ± 0.6% having 
an emergency room visit and 16.0 ± 0.6% being hospitalized. Physical inactivity was 
associated with 26.0 ± 6.7% greater total and 18.5 ± 5.4% greater out-of-pocket 
health care expenses (both p < 0.00001). Physical inactivity also was associated with 
a 23.9 ± 12.4% increase in the odds of an emergency room visit (p = 0.032) and a 
38.4 ± 15.2% increase in the odds of a hospitalization (p = .003). CONCLUSIONS: 
We found strong associations between physical inactivity and greater health care 
expenditures and health care resource use in patients with hypertension. Further 
research is warranted to identify amenable barriers to physical activity in this 
population.
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OBJECTIVES: To estimate incremental health care expenditure associated with 
comorbid cardiovascular disease (CVD) among patients with chronic obstructive 
pulmonary disease (COPD) in the hospital setting. METHODS: Retrospective data 
derived from the 2007 National Inpatient Sample (NIS) of the Healthcare Cost Utiliza-
tion Project (HCUP) was analyzed. Hospital inpatient discharge records for patients 
with a primary diagnosis of COPD and who were ≥40 years of age; were extracted 
to form the study sample. The sample was then categorized into two groups based on 
whether there was a secondary diagnosis of CVD. Incremental health care expenditure 
due to comorbid CVD was then determined by comparing hospital charges among 
the two groups. In addition to hospital charges, national estimates of hospital length 
of stay (LOS) and in-hospital mortality were also examined and compared between 
the two groups. For patients with COPD and comorbid CVD, the outcomes were 
compared across the different CVDs (hypertension, heart failure, ischemic heart 
disease, pulmonary heart disease, cerebrovascular disease, and cardiomyopathy and 
dysarrythmia). RESULTS: Of the 114,812 COPD-related hospital discharges in 2007; 
78.23% (n = 89,822) had CVD listed as a secondary diagnosis. Mean hospital charges 
were $15,691(95% CI $14,943 $16,439) for patients with COPD and no comorbid 
CVD, and were $23,986 (95% CI $23,012.59 $24,959.22) for patients with COPD 
and CVD. Among COPD patients with comorbid CVD, the mean charges were highest 
for those with cardiomyopathy and dysarrythmia, at $25,359(95%CI$24,052.96 
$26,664.45). The mean LOS was also higher among COPD patients with comorbid 
CVD as compared to those without comorbid CVD (4.59 days vs. 4.16 days). The 
mean LOS was also longest for patients with cardiomyopathy and dysarrythmia at 
5.75 days. CONCLUSIONS: Health care expenditure due to comorbid CVD is sub-
stantial among hospitalized patients with COPD.
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OBJECTIVES: To understand community-based treatment in hypertension patients 
status, care-seeking behavior, medical care, cost burden, and analyze impact factors 
of their behavior and self-prevention and control effect, China Health Insurance 
Research Association developed a research on evaluation on drugs and medical cost 
of hypertension patients in China, and reduce the cost burden of those patients. 
METHODS: This study collected 1788 valid samples as well as structured question-
naire survey in 3 cities from retrospective study. A more comprehensive medical 
management and settlement model has provided through an integrated qualitative and 
quantitative data analysis. The data was analyzed by Spss12.0, discriminant analysis; 
Chi-square test, one-way MANOVA, and multivariate linear regression analysis. 
RESULTS: 1)80% outpatients’ cumulative frequency of patients with hypertension 
concentrates upon about 110 medicines and the spending in these 110 drugs cumu-
lated 75% of all Western medicine fees. The average cost of outpatients in western 
medicine was RMB 69.4 Yuan; Insurers spent about 97.2% of their premium revenues 
on patient medicine cost. 2)80% inpatients’ cumulative frequency of patients with 
hypertension concentrates upon about 100 medicines and the spending in these 100 
drugs cumulated 50% of all Western medicine fees. The average cost of inpatients in 
western medicine was RMB 35.1 Yuan; Insurers spent about 91.3% of their premium 
on inpatient medicine cost.3) Statistic analysis outcomes show that course of the 
disease(x1), the type of high blood pressure(x2), the numbers of complications(x3) and 
the types of Standard management(x4) have signiﬁcant inﬂuence on the total hyperten-
sion treatment fees. By multivariate linear regression analysis, a safe regression mode 
was reached as follows: y = 3936.51 + 1294.309*X3 − 1239.323*X4. CONCLU-
SIONS: The categories of drugs administrated by hypertension patients concentrate 
in large cities, the spending in drugs was lower and the proportion of claims was high. 
The standard based on community health centers can lower the cost of hypertension 
treatment.
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OBJECTIVES: Computed Tomography (CT) is widely used as a diagnostic tool for 
medical conditions of the head, chest, cardiac, pulmonary and abdominal system. The 
objective of this retrospective study was to identify predictors of CT scan use in 
emergency department (ED) of hospitals in the United States amongst patients suffer-
ing from Coronary Artery Disease (CAD). METHODS: ED component of National 
Hospital Ambulatory Medical Care Survey (NHAMCS) for years 2005 and 2006 was 
used for the analysis. Patients were identiﬁed based on chief complaint, physician 
diagnosis and discharge diagnosis for CAD by ICD 9 codes or reason for visit codes. 
The binary outcome variable was use of CT scan. Independent variables were selected 
based on available literature on utilization of health services and general demograph-
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ics. SAS version 9.2 was used for analyses of data. Descriptive statistics were obtained 
by using survey frequency procedures that accounted for survey design and weighting. 
Weighted analyses were performed using survey logistic procedure controlling for 
interactions amongst the independent variables. RESULTS: During the 2 year period 
from 2005 and 2006, 3500 patients representing 12,769,828 CAD patients were 
identiﬁed. A total of 340 CAD patients representing 1,229,496 patients underwent 
CT scan procedure. Observations with missing data were deleted as it constituted less 
than 1% of the total identiﬁed population. Following variables were found signiﬁ-
cantly associated with probability of getting a CT scan: Painlevel, EKG use, Physician 
seen, Physician assistant seen, Race/ethnicity and Mode of arrival. These variables 
do not act in isolation and interactions between them were considered in the analyses 
CONCLUSIONS: The use of CT scan as a diagnostic tool in CAD patients admitted 
in ED depends on a multitude of interdependent factors such as patient characteristics 
deﬁned by painlevel, race/ethnicity, provider characteristics or the type of provider 
seen and type of health service utilized such as ambulance and concurrent EKG use.
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OBJECTIVES: Better selection of ischemic stroke patients for intravenous recombi-
nant tissue plasminogen activator (IV tPA) treatment based on the penumbral hypoth-
esis as seen through magnetic resonance imaging (MRI) by may improve clinical 
outcomes. However given the limited availability of MRIs in hospitals, MRI-based 
methods may not be feasible. We examined the cost-effectiveness of adding perfusion 
imaging with computed tomography (CTP) to usual computed tomography (CT)-
based methods to examine presence and extent of penumbra such that patients can 
be identiﬁed for IV tPA treatment. METHODS: A decision-analytic model was devel-
oped to estimate costs and outcomes associated with selecting patients for IV tPA 
treatment via CTP compared to current usual care of selection based on CT scan and 
patient history from a hospital perspective. The patient population was similar to that 
observed in the IV tPA clinical trials included in a recent meta-analysis. Clinical data 
was derived from published clinical trials. Costs were obtained from standard US 
costing sources and utilities were obtained from published literature. All costs are 
presented in 2009 US dollars. Outcomes included cost per life-year saved and cost per 
quality-adjusted life-year (QALY) gained. Sensitivity analyses were conducted. 
RESULTS: From the hospital perspective, the addition of penumbral-based CTP selec-
tion improved favorable outcome (modiﬁed Rankin Scale ≤1) by 0.59% and reduced 
cost by $42 compared with usual CT-based selection at hospital discharge. Life years 
and QALYs improved which resulted in the addition of penumbral-based CTP selec-
tion in being cost-savings to hospitals. Multivariate sensitivity analysis predicted 
cost-effectiveness (≤$50,000 per QALY) in 89.2% of simulation runs. CONCLU-
SIONS: Given costs and the limited availability of MRI, penumbral-based CTP after 
routine CT is a cost effective alternative for hospitals in selecting ischemic stroke 
patients for IV tPA treatment.
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OBJECTIVES: The recent re-label of clopidogrel to include information on CYP2C19 
genotype and the approval of a second-generation antiplatelet medication, prasugrel, 
could greatly impact the way antiplatelet therapy is prescribed. This study assesses the 
cost-effectiveness of genotyping patients to guide selection of antiplatelet therapy with 
clopidogrel or prasugrel. METHODS: A decision tree was created using prevalence 
of CYP2C19 metabolism status, cardiovascular events, and bleeding events and costs 
of events as reported in the literature and publically available FDA advisory committee 
documents. In the genotype arm, an individual’s metabolic status determined medica-
tion selection. Effect was deﬁned as the cost per event avoided. Scenario analyses that 
were conducted to determine the robustness of the model included scenario A: clopi-
dogrel use without genotyping and scenario B: prasugrel use without genotyping. 
Number needed to genotype to avoid one cardiovascular or bleeding event from 
occurring was also determined. RESULTS: The probability of being an ultra-rapid or 
extensive metabolizer of CYP2C19 was 73% and the probability of being an inter-
mediate or poor metabolizer was 27%. For the no-genotype arm, the estimated pro-
portions of medication selection used were 70% to receive clopidogrel and 30% to 
receive prasugrel. The model favored the intervention of genotyping patients to deter-
mine antiplatelet therapy (ICER: −$20,049). Both scenario analyses exhibited a domi-
nant strategy of genotyping patients (ICERA: −$21,833 and ICERB: −$15,918). 
Number needed to genotype to avoid one bleeding or cardiovascular event was 26. 
CONCLUSIONS: The cost-effectiveness analysis suggests it is more effective and less 
costly to genotype patients prior to selecting clopidogrel or prasugrel for the patient’s 
antiplatelet therapy.
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OBJECTIVES: Patients who self-discharge against medical advice (AMA) may be at 
higher risk for a hospital readmission if the unauthorized discharge was premature. 
The study objective is to examine the relationship between discharges AMA and 
cardiovascular disease (CVD) hospital readmissions while addressing bias due to 
potential confounding, selection, and hospital-level clustering. METHODS: This 
cross-sectional study uses conﬁdential inpatient hospital discharge data covering the 
years 2000 to 2005. The outcome variables captured readmissions for a CVD-related 
condition following an index CVD-related admission. The covariate of interest was 
an indicator variable for a discharge AMA in the index hospitalization. The relation-
ship between discharges AMA and 7-day, 31-day, 180-day, and 365-day hospital 
readmissions was examined using generalized linear models with adjustments for 
clustering and selection bias. RESULTS: The sample included 443,088 patients, of 
which 22,757 (5.1%) were readmitted to the same hospital. Approximately 1% of 
the patients who were readmitted in the hospital during the study period left AMA 
on the index admission while 0.89% of those who were not readmitted left AMA (p 
= 0.047). The odds of a CVD-related readmission within 7 days, 31 days, 180 days 
and 365 days were 145% (p < 0.001), 55% (p < 0.001), 26% (p < 0.001) and 15% 
(p = 0.0011) higher for patients discharged AMA on index admission compared to 
those who were discharged formally. Results are robust to corrections for observable 
selection bias (via propensity score analysis) and hospital-level clustering. CONCLU-
SIONS: A self-discharge AMA among patients admitted for CVD is predictive of 
CVD-related readmissions and the strength of association increases as the time 
between admissions decreases.
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OBJECTIVES: Future reﬁnement of pharmacotherapy of atrial ﬁbrillation/atrial ﬂutter 
(AF) requires a detailed understanding of how treatments are currently employed in 
clinical practice. METHODS: In this retrospective cohort study, we used the US 
MarketScan® database to identify patients ≥18 years with AF (≥1 AF inpatient or ≥2 
outpatient AF claims) and ≥18 months’ continuous enrollment data between Jan 2003 
and Sept 2007. The ﬁrst qualifying AF diagnosis following 12 months’ enrollment was 
designated the index diagnosis. AF was classiﬁed as newly-diagnosed (ND) or pre-
existing (PRE), based on treatment history in the pre-index period. RESULTS: Of 
184,155 identiﬁed patients (mean age 73 years, 55% men), 64,669 had ND and 
119,486 had PRE AF. Non-pharmacotherapy for AF was undertaken in 11% of 
patients with ND vs 6% of patients with PRE disease, most commonly cardioversion 
(9% vs. 4% of patients, respectively). Across both patient groups, 30% received no 
drug therapy within 30 days of initial AF diagnosis (initial treatment), 17% received 
antiarrhythmics (rhythm-control agents), 51% rate-control agents, 40% anticoagu-
lants, and 5% antiplatelets (aspirin use was not captured). Median duration of uninter-
rupted initial therapy was 210 days for antiarrhythmics and antiplatelets, 228 days 
for anticoagulants and 420 days for rate-control agents. Over the entire post-index 
follow-up period (mean 20 months), ND and PRE AF patients received antiarrhyth-
mics (27% vs 28%), rate-control agents (77% vs 76%), anticoagulants (54% vs. 66%) 
and antiplatelets (14% vs. 10%). Overall, the most commonly used drugs were amio-
darone (15%), β-blockers (56%), calcium channel blockers (23%), cardiac glycosides 
(35%), warfarin (61%) and clopidogrel (11%). CONCLUSIONS: Non-pharmacolog-
ical interventions for AF were relatively uncommon. Almost one-third of AF patients 
in our study remained untreated for the ﬁrst 30 days after diagnosis, which may 
represent under-treatment. Rate-control agents and anticoagulants were used more 
frequently than antiarrhythmics and antiplatelets for treatment of AF.
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OBJECTIVES: Coincident with the increasing focus on comparative effectiveness 
research (CER), a number of organizations have begun to engage in prioritizing 
topics for CER. This paper presents the priority-setting process developed by the 
Center for Medical Technology Policy (CMTP) and its application to the selection 
of cardiac technologies. METHODS: We reviewed criteria and processes used by 
other organizations. We then developed a multi-stage process including, 1) horizon 
scanning; 2) topic nomination; 3) expert solicitation; 4) topic review and selection; 
5) criteria application and discussion by a expert workgroup, and 6) ﬁnal ranking 
of topics for varied research projects. After internally reﬁning a broad list to the 
top ten technologies, we convened an expert workgroup charged with ranking these 
top technologies using prospectively developed criteria. Experts were provided with 
a list of criteria and briefs summarizing clinical, economic, and ethical aspects of 
each technology. RESULTS: Topic nomination produced an initial list of approxi-
mately 40 technologies, which were narrowed to the top ten based on suitability 
for CMTP’s coverage with evidence development (CED) initiatives and guidelines 
